Time-to-event analyses HRs for event-based outcomes comparing semaglutide 2.4 mg versus placebo were estimated from a pre-specified Cox proportional hazards model with treatment group (semaglutide and placebo) as a binary variable, presented with two-sided 95% CIs and two-sided P values
Heading into January 2026, consumer search behavior shows rising interest in non-prescription approaches to metabolic wellness, particularly around GLP-1-related terminology as prescription medications remain highly discussed and regulated
Highlights of Prescribing Information: Contrave (naltrexone hydrochloride and bupropion hydrochloride) extended-release tablets, for oral use
For AD, doctors mostly use cholinesterase inhibitors and NMDA receptor antagonists
This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access 261,46 per year only 21,79 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
